Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis

Monteagudo-Martínez, Nuria; Pozo, Julián Solís García del; Nava, Eduardo; Ikuta, Ichiro; Galindo, Marı́a F.; Jordán, Joaquı́n

doi:10.1080/14787210.2021.1828865

Cited by 11 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding literature interactions may facilitate learning about this antibiotic, of which we have previously shown its efficacy and safety in a systematic review meta-analysis. 28 We performed two different search strategies to recognize and shed light on the dalbavancin literature. Our initial WOS database search for dalbavancin as a topic term had good recall but lacked precision.…”

Section: Resultsmentioning

confidence: 99%

“…This bibliometric analysis of the available dalbavancin literature focused on the analysis of the bibliometric characteristics of the top 100 most cited documents in the WOS database. Understanding literature interactions may facilitate learning about this antibiotic, of which we have previously shown its efficacy and safety in a systematic review meta‐analysis 28 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Global trends of dalbavancin: A bibliometric analysis

Monteagudo-Martínez

Pozo

Ikuta

et al. 2022

Clinical Pharmacy Therapeu

Self Cite

View full text Add to dashboard Cite

What is known and objective? Dalbavancin is used against gram‐positive pathogens such as Staphylococcus aureus in acute bacterial skin and skin‐structure infections. Methods Our main goal was to identify the key articles sustaining the current knowledge of this drug's therapeutic possibilities through a bibliometric analysis of the available literature. Results and discussion On 15 March 2021, we searched the Web of Science electronically for documents that contain within its title the term “dalbavancin.” We found a total of 675 documents that average 20.23 citations/publication with a density of 682.60 citations per/year, yielding an h‐index of 58. After ranking them by the number of times cited, we extracted the top 100 most‐cited records (T100). Number of citations/publication ranged from 13 to 231, publication years were 2002–2019, with the top‐cited article published in 2014. All T100 publications were written in English. JMI Laboratories was the institution with the most articles in the T100 (22 documents), and the United States was the top country (75 documents). Five authors participated in at least five of the T100, led by Jones RN with 20 articles. Positions #1, #2, #5, and #9 were clinical trials for acute bacterial skin and skin structure infections (ABSSSI), the on‐label indication for dalbavancin. Only one article in the top 10 (T10) was an off‐label indication that was published in 2005 with 186 citations, and occupied the third position among the T100. Using the VOSviewer© programme, we observed that the most used keywords were: dalbavancin, lipoglycopeptide, gram‐positive, osteomyelitis, vancomycin, and MRSA. What is new and conclusions? Our study identifies the most significant research on dalbavancin, including the highest impact publications, and highlights the recent trend of dalbavancin in new therapies. The T10 articles include the most important dalbavancin clinical trials, along with other studies and reviews that support the growing role of this antibiotic in clinical use. Emphasis has been on the favourable pharmacokinetic profile that allows administration once‐weekly, with minimal risk of severe adverse events.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Global trends of dalbavancin: A bibliometric analysis

Monteagudo-Martínez

Pozo

Ikuta

et al. 2022

Clinical Pharmacy Therapeu

Self Cite

View full text Add to dashboard Cite

show abstract

“…These differences explain why DA and ORI are given in a two-dose regimen, with each dose separated by one week or with a single higher dose, whereas TE is administered every 24 h for 7 to 14 days for SSSIs and for 7 to 21 days for HABP/VABP [ 66 ]. Several studies [ 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 ] have evaluated all these antibiotics in patients with complicated aSSTIs, generally evidencing that they were not inferior to traditional alternatives, including VAN, tedizolid, linezolid, and daptomycin. The safety and tolerability of DA and ORI are generally good.…”

Section: Glycopeptidesmentioning

confidence: 99%

“…The efficacy of DA in patients with Gram-positive infections, including S. aureus , was confirmed by a recent meta-analysis in which, together with studies enrolling aSSTI patients, patients with catheter-related bloodstream infections (CRBSIs) and osteomyelitis were included. In this study, the superiority of DA in comparison to standard treatment for the CRBSIs and osteomyelitis subgroups was evidenced [ 69 ].…”

Section: Glycopeptidesmentioning

confidence: 99%

New Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA)

et al. 2023

View full text Add to dashboard Cite

Staphylococcus aureus is an extremely virulent pathogen that is capable of quickly evolving and developing antibiotic resistance. To overcome this problem, new antibiotics have been developed. Some of these have been licenced for use in clinical practice, mainly for the treatment of adults with acute skin and soft tissue infections, in addition to both community-acquired pneumonia (CAP) and nosocomial pneumonia (hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia). In this paper, the main characteristics and clinical use of new licenced anti-staphylococcal drugs have been discussed. In vitro studies have demonstrated that some new anti-staphylococcal antibiotics have better antimicrobial activity and, at least in certain cases, more favourable pharmacokinetic properties and higher safety and tolerability than the presently available anti-staphylococcal drugs. This suggests that they may have a potential use in reducing the risk of failure of S. aureus therapy. However, an in-depth analysis of microbiological and clinical studies carried out with these new drugs seems to indicate that further studies need to be conducted before the problem of resistance of S. aureus to the antibiotics available today can be completely solved. Considering the overall available research, the drugs that are active against S. aureus appear to present a great therapeutic opportunity for overcoming resistance to traditional therapy. There are advantages in the pharmacokinetic characteristics of some of these drugs and they have the potential to reduce hospital stays and economic costs associated with their use.

show abstract

“…The two RCTs DISCOVER 1 and 2 demonstrated noninferiority of dalbavancin compared with vancomycin or linezolid with respect to early clinical response [55]. A recent meta-analysis of 10 trials showed that dalbavancin has similar clinical efficacy as vancomycin and linezolid for ABSSSIs routine care [56]. Its side effects include nausea, diarrhoea, pruritus, infusion reactions and red man syndrome [54].…”

Section: Parenteral Antibiotic Therapy For the Treatment Of Methicill...mentioning

confidence: 99%

New drugs for methicillin-resistant Staphylococcus aureus skin and soft tissue infections

Hindy

Haddad

Kanj

2021

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of reviewStaphylococcus aureus is a pathogen incriminated in skin and soft tissue infections (SSTIs), with methicillinresistant S. aureus (MRSA) becoming the predominant cause and representing a significant burden to the healthcare system. The last updated Infectious Diseases Society of America (IDSA) guidelines concerning MRSA infections and SSTIs management were published in 2011 and 2014, respectively. The UK updated guidelines for MRSA infection treatment were published in 2021. Older treatment options may be associated with toxicity and require frequent dosing. There is a paucity of recent reviews on the armamentarium of new agents for MRSA SSTIs treatment. Recent findingsSince 2005, several new antibiotics received a fast-track approval by the Food and Drug Administration (FDA) for SSTI treatment. These drugs include delafloxacin, omadacycline, tedizolid, ceftaroline, dalbavancin, oritavancin and telavancin. In this manuscript, we will review the data that led to these new drugs approval and discuss their advantages and disadvantages in MRSA SSTIs management. SummaryMRSA is a major cause of SSTIs. Several novel therapies covering MRSA were FDA-approved for SSTIs. However, the current IDSA guidelines for MRSA infection and SSTIs as well as the recently published UK guidelines on MRSA treatment only consider these drugs as alternative choices or do not mention them at all. Keywordsacute bacterial skin and skin structure infections, methicillin-resistant Staphylococcus aureus, skin and soft tissue infections admissions for SSTIs was increasing by 30% from 2000 to 2004, a more recent study showed a decrease of 15.8% in MRSA-related hospitalizations between 2010 and 2014 [7,8].Historically, community-acquired MRSA (CA-MRSA) was genetically different from hospitalacquired-MRSA (HA-MRSA) and could be clinically differentiated because it was essentially causing limited to uncomplicated SSTIs [9]. However, the

show abstract

Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis

Cited by 11 publications

References 40 publications

Global trends of dalbavancin: A bibliometric analysis

Global trends of dalbavancin: A bibliometric analysis

New Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA)

New drugs for methicillin-resistant Staphylococcus aureus skin and soft tissue infections

Contact Info

Product

Resources

About